<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00325325</url>
  </required_header>
  <id_info>
    <org_study_id>EVEROTAC</org_study_id>
    <nct_id>NCT00325325</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study on the Combination of Everolimus-Tacrolimus</brief_title>
  <official_title>A Pilot Study to Investigate Pharmacokinetic Characteristics of Everolimus in Patients Treated With Tacrolimus-Based Immunosuppression in De Novo Kidney Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Ramon y Cajal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitario Ramon y Cajal</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to address the pharmacokinetic (PK) profiles of everolimus and
      tacrolimus in combination in de novo kidney transplant recipients, comparing 1.5 and 3 mg per
      day of everolimus in fixed doses. For comparison purposes, pharmacokinetic profiles will be
      performed at first dose (abbreviated), 4th day, 14th day, and 42nd day post-transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To address the pharmacokinetic profiles of everolimus and tacrolimus in combination in de
      novo kidney transplant recipients, comparing 1.5 and 3 mg per day of everolimus in fixed
      doses. For comparison purposes, pharmacokinetic profiles will be performed at first dose
      (abbreviated), 4th day, 14th day, and 42nd day post-transplantation. Patients will receive
      triple therapy steroids, tacrolimus and everolimus. Tacrolimus will be administered at a dose
      of 0.15 mg/kg/day to achieve 10-15 ng/ml 14 days, and 5-10 thereafter. During the first 6
      weeks (the PK study period) everolimus will be assigned to fixed dose of 0.75 or 1.5 mg bid.
      After day 42, everolimus will be adjusted for 3-8 ng/ml and tacrolimus minimized to optimize
      graft function. Efficacy and safety parameters at 6 months post-transplantation will be
      secondary endpoints.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2006</start_date>
  <completion_date>June 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>12-hour PK profiles of everolimus and tacrolimus on day 14 post-transplantation with everolimus 1.5 mg versus 3 mg per day</measure>
  </primary_outcome>
  <enrollment>40</enrollment>
  <condition>Kidney Diseases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>everolimus and tacrolimus</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Kidney transplant recipients aged 18-65 years old with a presumed immediately
             functioning graft

        Exclusion Criteria:

          -  Non-functioning kidneys
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julio Pascual, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario Ramon y Cajal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gorka G Erauzquin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Cruces, Bilbao</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José M Morales, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital 12 de Octubre, Madrid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis Pallardó, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Dr Peset, Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ricardo Lauzurica, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Germans, Trias i Puyol, Badalona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Domingo del Castillo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Reina Sofía, Córdoba</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Josep M Grinyó, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Bellvitge, Barcelona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julio Pascual, MD</last_name>
    <phone>+34 91 3368018</phone>
    <email>julpascual@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Julio Pascual, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2006</study_first_submitted>
  <study_first_submitted_qc>May 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2006</study_first_posted>
  <last_update_submitted>October 25, 2006</last_update_submitted>
  <last_update_submitted_qc>October 25, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2006</last_update_posted>
  <keyword>Kidney Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

